[Estimation of plasma 25(OH)D vitamin level in patients with metabolic syndrome]. / Ocena stezenia 25(OH)D w osoczu chorych z objawami zespolu metabolicznego.

UNLABELLED: Cardiovascular diseases are a major public health problem in developed and developing countries. A number of recent studies point to the pleiotropic differentiated effects of vitamin D, the deficiency of which positively correlates with the increased risk for cardiovascular diseases, hypertension, dyslipidemia, obesity or metabolic syndrome (MS). Vitamin D deficiency has also been proven to affect the progression of atherosclerosis. THE AIM: of this study was to evaluate plasma 25(OH)D level in patients with MS. MATERIALS AND METHODS: The study included 268 patients with MS, 136 men and 132 women, aged 30-65 years (mean 59,62±9,21 years). The study group was divided according to the age and season. The concentration of 25-hydroxy vitamin D (25-OH-D) was assessed with the application of the LIAISON® test using chemiluminescent immunoassay (CLIA) technology. RESULTS: The mean plasma level of 25(OH)D was 14,56±7,81 ng/ml in MS patients and it was not significantly higher in women than men (15,14 ±3,29 ng/ml vs. 13,97±3,41 ng/ml, p>0,05). The lowest 25(OH)D concentration was noted in the oldest age group (9,24±4,78 ng/ml). The highest 25(OH)D concentration was noted in summer months (23,71±3,82 ng/ml). CONCLUSIONS: The concentration of vitamin D in the plasma of patients with MS was significantly lower than its recommendations. Age and season of the year were the factors strongly affecting the level of 25(OH)D in MS patients.